Hi there, it’s Jamie Nimmo, UK Business Editor in London. Hope you enjoy today’s Readout. Queuing, starting all conversations on the topic of the weather, self-deprecation: These are three typically British things, but probably not the “British values” Keir Starmer was talking about in his latest interview. The prime minister said that Donald Trump’s rhetoric on Iran — and how the US president thr...
Hi there, it’s Jamie Nimmo, UK Business Editor in London. Hope you enjoy today’s Readout. Queuing, starting all conversations on the topic of the weather, self-deprecation: These are three typically British things, but probably not the “British values” Keir Starmer was talking about in his latest interview. The prime minister said that Donald Trump’s rhetoric on Iran — and how the US president threatened to destroy that country’s civilisation — is contrary to British values . “Let me be really clear about this. They are not words I would use — ever use — because I come at this with our British values and principles,” Starmer told ITV News. It’s the latest sign that Starmer is distancing himself from Trump after previously being criticised for attempting to cosy up to him. Last month, the prime minister had what was described as his “Love Actually moment,” where he in effect stood up to the cocksure US president, just as Hugh Grant’s character (albeit a fictional one) eventually did in the 2003 movie. As Allegra pointed out earlier this week , Starmer is shaking off his image as a “Trump Whisperer” and is now more of a “Trump Baiter,” similar to Spain’s Pedro Sanchez. Starmer’s been heavily criticised — and sometimes belittled — by Trump since the Iran war began, over his decision not to commit British forces to the conflict or allow unrestricted use of military bases. Now the UK leader is firing back, though in typically British fashion. “I’m fed up with the fact that families across the country see their bills go up and down on energy, businesses’ bills go up and down on energy because of the actions of Putin or Trump,” Starmer said in the interview. Starmer was speaking in Bahrain as part of a tour of the Middle East aimed at shoring up relations with Gulf partners and discussing next steps as the allies seek to restore shipping through the Strait of Hormuz. His latest comments are also a sign that he’s positioning his Labour Party for the local elections next mon...
Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co. , people with knowledge of the matter said. Advent has also been studying a possible acquisition of PolyPeptide, the people said, asking not to be identified because the information is private. Any buyout firm pursuing a take-private deal could seek to te...
Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co. , people with knowledge of the matter said. Advent has also been studying a possible acquisition of PolyPeptide, the people said, asking not to be identified because the information is private. Any buyout firm pursuing a take-private deal could seek to team up with its billionaire controlling shareholder, Swedish businessman Frederik Paulsen Jr. , according to the people. Shares of Zug-based PolyPeptide have risen almost 20% this year, giving the company a market value of about 1 billion Swiss francs ($1.3 billion). PolyPeptide specializes in the development and manufacturing of synthetic peptides related to metabolism, notably targeting obesity and diabetes. The biotech has been going through a turnaround which was welcome by investors and is ramping up new facilities. It operates sites in Europe, the US and India. Deliberations are ongoing and there’s no certainty they will lead to a transaction, according to the people. PolyPeptide could also attract interest from other suitors, they said. Representatives for Advent, EQT and KKR declined to comment. A spokesperson for PolyPeptide said the company “remains focused on executing its strategic plan and delivering long-term value to its shareholders and customers,” declining to comment further.
Battery casing workshop at Gotion High-tech’s Feidong base in Hefei, Anhui province. Photo: VCG Chinese lithium battery stocks rallied Friday after four government ministries pledged to crack down on price wars and excessive competition, highlighting Beijing’s push to rein in overcapacity and stabilize prices. Shares of major manufacturers, including industry leader Contemporary Amperex Technology...
Battery casing workshop at Gotion High-tech’s Feidong base in Hefei, Anhui province. Photo: VCG Chinese lithium battery stocks rallied Friday after four government ministries pledged to crack down on price wars and excessive competition, highlighting Beijing’s push to rein in overcapacity and stabilize prices. Shares of major manufacturers, including industry leader Contemporary Amperex Technology Co. Ltd. (CATL) and Sunwoda Electronic Co. Ltd., surged after a government symposium held Thursday to address market disorder.
Yang Zhilin, founder of fast-rising start-up Moonshot AI, has become the latest artificial intelligence entrepreneur to meet Chinese Premier Li Qiang, as Beijing steps up its push to accelerate the digital transformation of manufacturing. The 32-year-old was among a select group of business leaders and experts invited to a high-level symposium on Friday, where participants offered views on China’s...
Yang Zhilin, founder of fast-rising start-up Moonshot AI, has become the latest artificial intelligence entrepreneur to meet Chinese Premier Li Qiang, as Beijing steps up its push to accelerate the digital transformation of manufacturing. The 32-year-old was among a select group of business leaders and experts invited to a high-level symposium on Friday, where participants offered views on China’s economic resilience and future growth drivers. Li acknowledged that the external environment had...
Alphabet's Google Has Given Birth to 3 Millionaire-Maker Stocks Hiding in Plain Sight. All of Them Are Trading at Incredible Valuations Right Now. The Motley Fool
Alphabet's Google Has Given Birth to 3 Millionaire-Maker Stocks Hiding in Plain Sight. All of Them Are Trading at Incredible Valuations Right Now. The Motley Fool
Chips have fueled the AI gold rush, sending valuations of stocks like Nvidia (NASDAQ:NVDA) soaring as investors piled in. Six months later, though, the hardware leader sits flat while diversified players quietly compound gains. The next trillion-dollar shift isn’t going to be about raw compute power; rather, it will be the embedding of intelligence into ... Forget Nvidia: This Stock Will Be More V...
Chips have fueled the AI gold rush, sending valuations of stocks like Nvidia (NASDAQ:NVDA) soaring as investors piled in. Six months later, though, the hardware leader sits flat while diversified players quietly compound gains. The next trillion-dollar shift isn’t going to be about raw compute power; rather, it will be the embedding of intelligence into ... Forget Nvidia: This Stock Will Be More Valuable in Less Than 1 Year
Replimune ( REPL ) shares tumbled before a trading halt on Friday after the U.S. Food and Drug Administration (FDA) declined to approve its lead candidate RP1 (vusolimogene oderparepvec) for the second time. The Massachusetts-based biotech’s resubmitted Biologics License Application (BLA) for RP1 was undergoing regulatory review with a target of April 10, 2026, after the FDA initially rejected the...
Replimune ( REPL ) shares tumbled before a trading halt on Friday after the U.S. Food and Drug Administration (FDA) declined to approve its lead candidate RP1 (vusolimogene oderparepvec) for the second time. The Massachusetts-based biotech’s resubmitted Biologics License Application (BLA) for RP1 was undergoing regulatory review with a target of April 10, 2026, after the FDA initially rejected the drug for a skin cancer known as melanoma last year. The company had sought the approval of RP1 in combination with nivolumab, marketed by Bristol Myers ( BMY ) as Opdivo, for those with advanced melanoma who had undergone anti-PD-1 containing treatments previously. Issuing a complete response letter on Friday, the FDA said that it is unable to approve the BLA due to a lack of sufficient data demonstrating RP1's efficacy as a combination therapy for unresectable advanced cutaneous melanoma. More on Replimune Group Replimune: Multiple Shots On Goal But A High Risk Binary Approaches Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Biotech firm stocks rise on FDA vaccine head’s exit Replimune Group GAAP EPS of -$0.77 beats by $0.01